Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Strong-Buy by BidaskClub

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday, January 18th.

Several other research firms have also recently issued reports on ARWR. Cantor Fitzgerald set a $2.00 price target on Arrowhead Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday, December 12th. B. Riley assumed coverage on Arrowhead Pharmaceuticals in a report on Friday, January 5th. They issued a “neutral” rating and a $3.00 price target on the stock. Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target on the stock in a report on Monday, November 27th. Finally, ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Five equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $4.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $5.31 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.63 and a current ratio of 3.63. Arrowhead Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $6.75. The stock has a market capitalization of $397.34, a price-to-earnings ratio of -11.30 and a beta of 2.52.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The business had revenue of $8.71 million for the quarter, compared to the consensus estimate of $7.32 million. Arrowhead Pharmaceuticals had a negative return on equity of 40.38% and a negative net margin of 116.17%. equities analysts anticipate that Arrowhead Pharmaceuticals will post -0.74 EPS for the current fiscal year.

In other news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the sale, the chief operating officer now owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Allianz Asset Management GmbH acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $1,958,000. Schwab Charles Investment Management Inc. increased its position in shares of Arrowhead Pharmaceuticals by 10.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 16,103 shares during the last quarter. First Manhattan Co. acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $11,707,000. Acadian Asset Management LLC increased its position in shares of Arrowhead Pharmaceuticals by 1,177.7% during the 4th quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 66,055 shares during the last quarter. Finally, ING Groep NV acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $3,500,000. 20.48% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/arrowhead-pharmaceuticals-arwr-upgraded-at-bidaskclub.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply